Expected commencement of pridopidine phase 3 trial in ALS patients likely this year
Fueled by promising HEALEY-ALS Phase 2 trial data, Prilenia Therapeutics is gearing up to initiate a pivotal Phase 3 study of pridopidine, its candidate treatment for amyotrophic lateral sclerosis (ALS), in the